Molecular markers of resistance to sulfadoxine-pyrimethamine during intermittent preventive treatment for malaria in mozambican infants

Journal of Infectious Diseases

Volumn 197, Issue 12, 2008, Pages 1737-1742

  Mayor, Alfredo ^a,c   Serra Casas, Elisa ^a,c   Sanz, Sergi ^a   Aponte, John J ^a,c   Macete, Eusebio ^c   Mandomando, Inacio ^a,c   Puyol, Laura ^a   Berzosa, Pedro ^b   Dobaño, Carlota ^a,c   Aide, Pedro ^c   Sacarla, Jahit ^a,c   Benito, Agustín ^b   Alonso, Pedro ^a,c   Menéndez, Clara ^a,c  

^a UNIVERSITY OF BARCELONA   (Spain)

^b Red de Investigación de Centros de Enfermedades Tropicales RICET Madrid   (Spain)

^c EDUARDO MONDLANE UNIVERSITY   (Mozambique)

Author keywords

[No Author keywords available]

Indexed keywords

FANSIDAR; PLACEBO;

ARTICLE; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CODON; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DHFR GENE; DHPS GENE; DOUBLE BLIND PROCEDURE; DRUG INTERMITTENT THERAPY; GENE; GENE MUTATION; HAPLOTYPE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALARIA CONTROL; MALARIA FALCIPARUM; MOZAMBIQUE; PARASITE ISOLATION; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ANIMALS; ANTIMALARIALS; BIOLOGICAL MARKERS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; DRUG RESISTANCE; FEMALE; HUMANS; INFANT; MALARIA, FALCIPARUM; MALE; MOZAMBIQUE; MUTATION; PLASMODIUM FALCIPARUM; PYRIMETHAMINE; SULFADOXINE;

EID: 46349110443     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/588144     Document Type: Article

References (30)

1. Egan A, Crawley J, Schellenberg D. Intermittent preventive treatment for malaria control in infants: moving towards evidence-based policy and public health action. Trop Med Int Health 2005; 10:815-7.
2. Schellenberg D, Menendez C, Kahigwa E, et al. Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial. Lancet 2001; 357:1471-7.
3. Chandramohan D, Owusu-Agyei S, Carneiro I, et al. Cluster randomised trial of intermittent preventive treatment for malaria in infants in area of high, seasonal transmission in Ghana. BMJ 2005; 331:727-33.
4. Macete E, Aide P, Aponte JJ, et al. Intermittent preventive treatment for malaria control administered at the time of routine vaccinations in Mozambican infants: a randomized, placebo-controlled trial. J Infect Dis 2006; 194:276-85.
5. Watkins WM, Mosobo M. Treatment of Plasmodium falciparum malaria with pyrimethamine-sulfadoxine: selective pressure for resistance is a function of long elimination half-life. Trans R Soc Trop Med Hyg 1993; 87:75-8.
6. Marks F, von Kalckreuth V, Kobbe R, et al. Parasitological rebound effect and emergence of pyrimethamine resistance in Plasmodium falciparum after single-dose sulfadoxine-pyrimethamine. J Infect Dis 2005; 192:1962-5.
7. Cisse B, Sokhna C, Boulanger D, et al. Seasonal intermittent preventive treatment with artesunate and sulfadoxine-pyrimethamine for prevention of malaria in Senegalese children: a randomised, placebo-controlled, double-blind trial. Lancet 2006; 367:659-67.
8. White NJ. Antimalarial drug resistance. J Clin Invest 2004; 113:1084-92.
9. Peterson DS, Walliker D, Wellems TE. Evidence that a point mutation in dihydrofolate reductase-thymidylate synthase confers resistance to pyrimethamine in falciparum malaria. Proc Natl Acad Sci USA 1988; 85:9114-8.
10. Triglia T, Menting JG, Wilson C, Cowman AF. Mutations in dihydropteroate synthase are responsible for sulfone and sulfonamide resistance in Plasmodium falciparum. Proc Natl Acad Sci USA 1997; 94:13944-9.
11. Plowe CV, Cortese JF, Djimde A, et al. Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase and epidemiologic patterns of pyrimethamine-sulfadoxine use and resistance. J Infect Dis 1997; 176:1590-6.
12. Kublin JG, Witzig RS, Shankar AH, et al. Molecular assays for surveillance of antifolate-resistant malaria. Lancet 1998; 351:1629-30.
13. Mberu EK, Nzila AM, Nduati E, et al. Plasmodium falciparum: in vitro activity of sulfadoxine and dapsone in field isolates from Kenya: point mutations in dihydropteroate synthase may not be the only determinants in sulfa resistance. Exp Parasitol 2002; 101:90-6.
14. Aubouy A, Jafari S, Huart V, et al. DHFR and DHPS genotypes of Plasmodium falciparum isolates from Gabon correlate with in vitro activity of pyrimethamine and cycloguanil, but not with sulfadoxine- pyrimethamine treatment efficacy. J Antimicrob Chemother 2003; 52:43-9.
15. Djimde A, Doumbo OK, Cortese JF, et al. A molecular marker for chloroquine-resistant falciparum malaria. N Engl J Med 2001; 344:257-63.
16. Foote SJ, Kyle DE, Martin RK, et al. Several alleles of the multidrug-resistance gene are closely linked to chloroquine resistance in Plasmodium falciparum. Nature 1990; 345:255-8.
17. Alonso PL, Smith T, Schellenberg JR, et al. Randomised trial of efficacy of SPf66 vaccine against Plasmodium falciparum malaria in children in southern Tanzania. Lancet 1994; 344:1175-81.
18. Robert F, Ntoumi F, Angel G, et al. Extensive genetic diversity of Plasmodium falciparum isolates collected from patients with severe malaria in Dakar, Senegal. Trans R Soc Trop Med Hyg 1996; 90:704-11.
19. Smith T, Felger I, Tanner M, Beck HP. Premunition in Plasmodium falciparum infection: insights from the epidemiology of multiple infections. Trans R Soc Trop Med Hyg 1999; 93:59-64.
20. Schellenberg D, Menendez C, Aponte JJ, et al. Intermittent preventive antimalarial treatment for Tanzanian infants: follow-up to age 2 years of a randomised, placebo-controlled trial. Lancet 2005; 365:1481-3.
21. Alexander N, Sutherland C, Roper C, Cisse B, Schellenberg D. Modelling the impact of intermittent preventive treatment for malaria on selection pressure for drug resistance. Malar J 2007; 6:9.
22. O'Meara WP, Smith DL, McKenzie FE. Potential impact of intermittent preventive treatment (IPT) on spread of drug-resistant malaria. PLoS Med 2006; 3:e141.
23. World Health Organization (WHO). A strategic framework for malaria prevention and control during pregnancy in the African region. AFR/MAL/04/01. Brazzaville, Republic of the Congo: WHO Regional Office for Africa, 2004.
24. Jelinek T, Ronn AM, Curtis J, et al. High prevalence of mutations in the dihydrofolate reductase gene of Plasmodium falciparum in isolates from Tanzania without evidence of an association to clinical sulfadoxine/ pyrimethamine resistance. Trop Med Int Health 1997; 2:1075-9.
25. Nzila AM, Mberu EK, Sulo J, et al. Towards an understanding of the mechanism of pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: genotyping of dihydrofolate reductase and dihydropteroate synthase of Kenyan parasites. Antimicrob Agents Chemother 2000; 44:991-6.
26. Ringwald P, Keundjian A, Same Ekobo A, Basco LK. Chemoresistance of Plasmodium falciparum in the urban region of Yaounde, Cameroon. Part 2: evaluation of the efficacy of amodiaquine and sulfadoxine-pyrimethamine combination in the treatment of uncomplicated Plasmodium falciparum malaria in Yaounde, Cameroon. Trop Med Int Health 2000; 5:620-7.
27. Basco LK, Tahar R, Keundjian A, Ringwald P. Sequence variations in the genes encoding dihydropteroate synthase and dihydrofolate reductase and clinical response to sulfadoxine-pyrimethamine in patients with acute uncomplicated falciparum malaria. J Infect Dis 2000; 182:624-8.
28. Omar SA, Adagu IS, Warhurst DC. Can pretreatment screening for dhps and dhfr point mutations in Plasmodium falciparum infections be used to predict sulfadoxine-pyrimethamine treatment failure? Trans R Soc Trop Med Hyg 2001; 95:315-9.
29. Alifrangis M, Enosse S, Khalil IF, et al. Prediction of Plasmodium falciparum resistance to sulfadoxine/pyrimethamine in vivo by mutations in the dihydrofolate reductase and dihydropteroate synthetase genes: a comparative study between sites of differing endemicity. Am J Trop Med Hyg 2003; 69:601-6.
30. White NJ. Why is it that antimalarial drug treatments do not always work? Ann Trop Med Parasitol 1998; 92:449-58.